<DOC>
	<DOCNO>NCT01939899</DOCNO>
	<brief_summary>This open-label , multicenter , phase 2 study evaluate efficacy safety oral IXAZOMIB adult patient follicular lymphoma ( FL ) relapse and/or refractory prior treatment .</brief_summary>
	<brief_title>Phase 2 Study Oral IXAZOMIB Adult Patients With Relapsed and/or Refractory Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Ixazomib</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>Male female patient 18 year old Patients must pathologically confirm diagnosis nonHodgkin lymphoma ( NHL ) ( leadin dosefinding phase ) FL ( phase 2 ) Patients must radiographically clinically measurable disease Patients must relapse and/or refractory least 1 prior therapy ( exclude radiation ) document progressive disease time enrollment Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Female patient post menopausal , surgically sterile , agree practice 2 effective method contraception agree practice true abstinence Male patient agree practice effective barrier contraception agree practice true abstinence Voluntary write consent Suitable venous access Appropriate clinical laboratory value define protocol Recovered toxicity prior anticancer therapy If trial proceeds second step basis tandem 2step design , patient must confirm PSMB1 positive central laboratory treatment Exclusion Criteria Peripheral neuropathy great equal Grade 2 Grade 1 pain Female patient lactate breastfeed positive serum pregnancy test Screening period Autologous stem cell transplant within 6 month Day 1 Cycle 1 , prior allogeneic stem cell transplant time Major surgery within 14 day first dose study drug Infection require systemic antibiotic therapy serious infection within 14 day first dose study drug Comorbid systemic illness severe concurrent disease , judgment investigator , would make patient inappropriate entry study interfere significantly proper assessment safety toxicity prescribe regimens Evidence current uncontrolled cardiovascular condition include uncontrolled hypertension , severe uncontrolled ventricular arrhythmia , unstable angina , New York Heart Association ( NYHA ) Class III IV cardiac disease , myocardial infarction within past 6 month Diarrhea &gt; Grade 1 basis NCI CTCAE categorization Systemic antineoplastic ( include glucocorticoid &gt; equivalent 15 mg prednisone daily ) , experimental , radiation therapy within 21 day first dose study drug Prior treatment rituximab unconjugated antibody treatment within 42 day ( 21 day clear evidence progressive disease immediate treatment mandate ) Treatment radioimmunoconjugates toxin immunoconjugates within 12 week first dose study treatment Systemic treatment strong inhibitor CYP1A2 CYP3A , strong CYP3A inducer within 14 day first dose IXAZOMIB Ongoing systemic therapy corticosteroid Central nervous system ( CNS ) involvement clinically uncontrolled newly diagnose last 4 month Ongoing active systemic viral infection , know human immunodeficiency virus ( HIV ) positive , know active hepatitis B virus know active hepatitis C virus Diagnosed treat another malignancy within 2 year study enrollment previously diagnose another malignancy evidence residual disease exception nonmelanoma skin cancer completely resect carcinoma situ Platelet transfusion within 3 day 1st dose study drug Inability swallow capsule , inability unwillingness avoid take anything mouth except water prescribe medication 2 hour 1 hour dose IXAZOMIB Known allergy boron excipients formulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>MLN9708</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>IXAZOMIB</keyword>
</DOC>